AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX

Key Points

• AIGH Capital Management purchased 1,500,000 shares of Kyverna Therapeutics valued at about $14.1 million, making KYTX roughly 3.4% of AIGH's portfolio and its 11th-largest holding (AIGH owns ~3.42% of Kyverna per its SEC filing).
• Analyst sentiment is mixed — four Buys and one Sell yield a MarketBeat average rating of Moderate Buy with an average target price of $28.67, though some firms recently downgraded the stock while HC Wainwright reaffirmed a Buy with a $20 target.
• Kyverna is a clinical-stage biotech developing engineered regulatory T‑cell therapies (lead allogeneic Treg candidate for ulcerative colitis); shares trade around $8.87 with a market cap near $537 million and negative earnings (last quarter EPS −0.80; analysts expect −3.18 for the year).

AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,500,000 shares of the company's stock, valued at approximately $14,100,000. Kyverna Therapeutics comprises about 3.4% of AIGH Capital Management LLC's portfolio, making the stock its 11th biggest holding. AIGH Capital Management LLC owned about 3.42% of Kyverna Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Kyverna Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company's stock valued at $7,936,000 after acquiring an additional 9,858 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Kyverna Therapeutics by 21.9% during the 3rd quarter. Millennium Management LLC now owns 551,635 shares of the company's stock valued at $3,310,000 after acquiring an additional 99,075 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter valued at about $1,513,000. Bridgeway Capital Management LLC boosted its holdings in shares of Kyverna Therapeutics by 178.1% during the 3rd quarter. Bridgeway Capital Management LLC now owns 174,900 shares of the company's stock valued at $1,049,000 after acquiring an additional 112,000 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Kyverna Therapeutics by 60.4% during the 3rd quarter. UBS Group AG now owns 157,422 shares of the company's stock valued at $945,000 after acquiring an additional 59,264 shares during the last quarter. Hedge funds and other institutional investors own 18.08% of the company's stock.

Analyst Ratings Changes

KYTX has been the topic of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Wall Street Zen downgraded shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Kyverna Therapeutics in a report on Thursday, April 23rd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $28.67.

Kyverna Therapeutics Stock Up 0.8%

Shares of KYTX opened at $8.87 on Friday. The firm has a market capitalization of $536.90 million, a P/E ratio of -2.43 and a beta of 2.06. Kyverna Therapeutics, Inc. has a 12-month low of $1.92 and a 12-month high of $13.67. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11. The firm has a fifty day moving average price of $8.73 and a 200-day moving average price of $8.19.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.80). Equities research analysts expect that Kyverna Therapeutics, Inc. will post -3.18 earnings per share for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.